Johnson & Johnson News
Johnson & Johnson Pharmaceutical Company News
Metabolic Effects Significantly Lower With INVEGA® Compared to Olanzapine(Nov 18, 2009)
Beerse, Belgium (November 18th 2009)-- New data from a 6-month open label randomised controlled trial show INVEGA® (paliperidone ER) is associated with significantly less metabolic effects compared to oral olanzapine in people with schizophrenia, while demonstrating comparable efficacy. The results were presented today at the 15th Biennial Winter Workshop in Psychoses in Barcelona, Spain.....
National Expressions of Courage Art Contest Unveils Stories of Inspiration(Nov 16, 2009)
Raritan, NJ (November 16, 2009 - Epilepsy and seizures affect nearly 3 million Americans of all ages and in 70 percent of new cases, no cause is apparent. Those who live daily with the condition have no way of knowing when the next seizure will occur, how long it will last or where they will be, often experiencing a roller coaster of emotions as they cope with the condition.
DePuy plans to phase out manufacture at Leeds facility(Nov 12, 2009)
November 12, 2009 - Following a detailed review of its global production requirements versus capacity, DePuy intends to phase out manufacturing at its facility in St. Anthony’s Road, Beeston, Leeds, subject to statutory consultation. The company plans to rationalise its product portfolio to focus on lines that best meet the current and emerging needs of surgeons and patients.
Longer Prescribed Replacement Intervals Leads to More Stretching of Frequent Replacement Contact Lenses(Nov 11, 2009)
Orlando, FL (November 11, 2009) – Contact lenses prescribed for longer replacement intervals can lead to more extreme over wear (stretching) that could lead to undesirable clinical effects, new research shows.....
Analysis Underscores Financial Burden of Mental Illness on Criminal Justice and Health Care Systems(Nov 11, 2009)
Philadelphia, PA (November 11, 2009) – Results from a large, retrospective analysis of inmates with a serious mental illness (SMI) underscores the financial burden of mental illness on the criminal justice and health and human services (HHS) systems, and may provide useful information to policy makers.
McNeil Consumer Healthcare Announces Voluntary Recall of Certain Lots of TYLENOL® Arthritis Pain 100 Count with EZ-OPEN CAP(Nov 6, 2009)
Fort Washington, PA (November 6, 2009) - In consultation with the U.S. Food and Drug Administration (FDA), McNeil Consumer Healthcare, Division of McNEIL-PPC, Inc., is initiating a voluntary recall of a limited number of product lots of TYLENOL® Arthritis Pain Caplet 100 count bottles, with the distinctive red EZ-OPEN CAP.
Neutrogena Launches Online Holiday Shopping Destination(Nov 9, 2009)
Los Angeles, CA (November 9, 2009) – Neutrogena®, the #1 dermatologist recommended skincare brand, today launches , where consumers can shop this season’s best beauty buys for family and friends.
Johnson & Johnson to Participate in Credit Suisse 18th Annual Health Care Conference(Nov 5, 2009)
New Brunswick, NJ (November 5, 2009) -- Johnson & Johnson will participate in the Credit Suisse 18 Annual Health Care Conference on Thursday, Nov. 12, at the Arizona Biltmore Hotel. Dominic Caruso, Vice President, Finance and Chief Financial Officer, will present in a session scheduled at 10:00 a.m. (Mountain Time) or 12:00 p.m. (Eastern Time).....
CONCERTA® in the Classroom: New Data on Attention in Children With ADH(Nov 4, 2009)
>Las Vegas, NV (November 4th, 2009) -- New findings presented today show that CONCERTA® (OROS® methylphenidate HCl Extended-Release Tablets CII) is the only stimulant medication with data that demonstrate a significant treatment effect on attention at one hour and through 12.5 hours in children with Attention Deficit Hyperactivity Disorder (ADHD).
Lesser-Known Effects of Smoking Can Play Havoc with Women's Health(Nov 4, 2009)
Toronto, Canada (November 4th, 2009)- Many women are aware that smoking can lead to lung cancer, heart disease and premature death.
